Merck KGaA (FRA:MRK) received a €120.00 ($148.15) price objective from stock analysts at UBS Group in a note issued to investors on Friday, www.boersen-zeitung.de reports. The brokerage currently has a “buy” rating on the healthcare company’s stock. UBS Group’s price target would suggest a potential upside of 43.68% from the stock’s current price.
MRK has been the subject of several other research reports. Sanford C. Bernstein set a €115.00 ($141.98) price target on Merck KGaA and gave the stock a “buy” rating in a research note on Wednesday, November 29th. Bank of America set a €95.00 ($117.28) price objective on Merck KGaA and gave the stock a “neutral” rating in a research report on Wednesday, December 6th. Commerzbank set a €103.00 ($127.16) price objective on Merck KGaA and gave the stock a “neutral” rating in a research report on Thursday, November 9th. JPMorgan Chase & Co. set a €100.00 ($123.46) price objective on Merck KGaA and gave the stock a “neutral” rating in a research report on Wednesday, November 8th. Finally, Morgan Stanley set a €98.00 ($120.99) price objective on Merck KGaA and gave the stock a “neutral” rating in a research report on Friday, December 1st. Eleven investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of €107.57 ($132.80).
Shares of Merck KGaA (FRA:MRK) opened at €83.52 ($103.11) on Friday. The stock has a market capitalization of $10,790.00 and a PE ratio of 19.56. Merck KGaA has a 52 week low of €80.50 ($99.38) and a 52 week high of €115.00 ($141.98).
WARNING: “Merck KGaA (MRK) Given a €120.00 Price Target at UBS Group” was posted by The Lincolnian Online and is the property of of The Lincolnian Online. If you are accessing this article on another site, it was stolen and republished in violation of US & international copyright legislation. The correct version of this article can be viewed at https://www.thelincolnianonline.com/2018/02/18/merck-kgaa-mrk-given-a-120-00-price-target-at-ubs-group.html.
About Merck KGaA
MERCK Kommanditgesellschaft auf Aktien provides products in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat colorectal cancer, head and neck tumors, multiple sclerosis, infertility, growth hormone disorders, cardiovascular disorders, diabetes, and thyroid disorders; diagnostics and prescription drugs for allergen immunotherapy; and biosimilars for oncology and inflammatory disorders.
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.